AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15446522 — intervention group
Group type: EXPERIMENTAL
Intervention: ACL-PCL and MLP
Number of subjects: 344
Study 11422013 — intervention group
Group type: EXPERIMENTAL
Intervention: oral ARTS (150 mg)
Number of subjects: 25
Study 11422013 — intervention group
Group type: EXPERIMENTAL
Intervention: oral DHA (120 mg)
Number of subjects: 25
Study 10447842 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized patients with a tutor to student ratio of 1.5:10
Number of subjects: 75
Study 10447842 — intervention group
Group type: COMPARATOR
Intervention: Control group with traditional inpatient encounters and a tutor to student ratio of 3:10
Number of subjects: 75
Study 10447842 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group
Number of subjects: 75
Study 10447842 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 75
Study 8549572 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrose solution (330 ml with 150 mg sodium 1-[13C] acetate)
Number of subjects: 6
Study 8549572 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose polymer solution (330 ml with 150 mg sodium 1-[13C] acetate)
Number of subjects: 6
Study 8549572 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose solution (330 ml with 150 mg sodium 1-[13C] acetate)
Number of subjects: 6
Study 8549572 — intervention group
Group type: COMPARATOR
Intervention: Water (330 ml)
Number of subjects: 6
Study 2356344 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.75% (15 ml)
Number of subjects: 77
Study 2356344 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.75% (20 ml)
Number of subjects: 77
Study 2356344 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.75% (25 ml)
Number of subjects: 77
Study 2356344 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine 0.75% (15 ml)
Number of subjects: 77
Study 2356344 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine 0.5% (15 ml)
Number of subjects: 77
Study 116537 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralipid infusion
Number of subjects: 12
Study 31092139 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management intervention
Number of subjects: 91
Study 31092139 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 91
Study 30172900 — intervention group
Group type: EXPERIMENTAL
Intervention: Lettuce seed (1000 mg daily for two weeks)
Number of subjects: 100
Study 30172900 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 26898299 — intervention group
Group type: EXPERIMENTAL
Intervention: Amatuximab
Number of subjects: 0
Study 23839031 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual adaptation with visual cues
Number of subjects: 0
Study 23839031 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual adaptation with postural cues
Number of subjects: 0
Study 23839031 — intervention group
Group type: COMPARATOR
Intervention: Single adaptation
Number of subjects: 0
Study 22257013 — intervention group
Group type: EXPERIMENTAL
Intervention: MF101
Number of subjects: 217
Study 22257013 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 217
Study 20356440 — intervention group
Group type: EXPERIMENTAL
Intervention: Xuebijing injection (treatment group)
Number of subjects: 33
Study 20356440 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (control group)
Number of subjects: 33
Study 18793398 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavior therapy for depression prior to standard weight loss treatment
Number of subjects: 174
Study 18793398 — intervention group
Group type: COMPARATOR
Intervention: Standard weight loss treatment alone
Number of subjects: 174
Study 16354802 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitamaquine 1.5 mg kg(‐1) day(‐1)
Number of subjects: 120
Study 16354802 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitamaquine 1.75 mg kg(‐1) day(‐1)
Number of subjects: 120
Study 16354802 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitamaquine 2.0 mg kg(‐1) day(‐1)
Number of subjects: 120
Study 16354802 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitamaquine 2.5 mg kg(‐1) day(‐1)
Number of subjects: 120
Study 14668277 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg lysine/kg/d
Number of subjects: 14
Study 14668277 — intervention group
Group type: EXPERIMENTAL
Intervention: 45 mg lysine/kg/d
Number of subjects: 14
Study 10375057 — intervention group
Group type: EXPERIMENTAL
Intervention: High-carbohydrate (HC) diet (protein 12% of total energy)
Number of subjects: 65
Study 10375057 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein (HP) diet (protein 25% of total energy)
Number of subjects: 65
Study 10375057 — intervention group
Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 65
Study 8728664 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft splint
Number of subjects: 39
Study 8728664 — intervention group
Group type: EXPERIMENTAL
Intervention: Hard splint
Number of subjects: 39
Study 8728664 — intervention group
Group type: COMPARATOR
Intervention: Unsplinted control
Number of subjects: 39
Study 1521727 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (10-20 mg/day) for 12 weeks
Number of subjects: 26
Study 1521727 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment for 12 weeks
Number of subjects: 26
Study 1521727 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin treatment (baseline vs 12 weeks)
Number of subjects: 26
Study 1521727 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment (baseline vs 12 weeks)
Number of subjects: 26
Study 6651612 — intervention group
Group type: EXPERIMENTAL
Intervention: Colestipol (30 grams/day), Niacin (7.3 grams/day), and diet
Number of subjects: 14
Study 6651612 — intervention group
Group type: COMPARATOR
Intervention: Placebo and diet
Number of subjects: 14
Study 4027129 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular coffee
Number of subjects: 12
Study 4027129 — intervention group
Group type: COMPARATOR
Intervention: Decaffeinated coffee
Number of subjects: 12
Study 30916916 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirror therapy (MT) and motor imagery (MI)
Number of subjects: 22
Study 30916916 — intervention group
Group type: COMPARATOR
Intervention: Traditional rehabilitation (mime-therapy and myofascial-approach)
Number of subjects: 22
Study 29220110 — intervention group
Group type: EXPERIMENTAL
Intervention: Strong opioids (specific types not mentioned)
Number of subjects: 498
Study 29220110 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal opioids
Number of subjects: 498
Study 29220110 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl
Number of subjects: 498
Study 29220110 — intervention group
Group type: EXPERIMENTAL
Intervention: Polypharmacological therapy
Number of subjects: 498
Study 29220110 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidiabetic drugs, antibiotics, previous weak opioid therapy
Number of subjects: 498
Study 29220110 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulant, antidiabetic, and central nervous system drugs
Number of subjects: 498
Study 29220110 — intervention group
Group type: EXPERIMENTAL
Intervention: High rating on the Karnofsky Performance Status Index
Number of subjects: 498
Study 29220110 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term opioids
Number of subjects: 498
Study 27327862 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose bolus tirofiban
Number of subjects: 83
Study 27327862 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-bolus eptifibatide
Number of subjects: 83
Study 27327862 — intervention group
Group type: EXPERIMENTAL
Intervention: Abciximab followed by a 12-hour infusion
Number of subjects: 83
Study 27327862 — intervention group
Group type: COMPARATOR
Intervention: Ticagrelor or prasugrel
Number of subjects: 83
Study 27327862 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 83
Study 24710131 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone 7.5 mg/day in addition to disease-modifying antirheumatic drugs (DMARDs)
Number of subjects: 223
Study 24710131 — intervention group
Group type: COMPARATOR
Intervention: DMARD therapy alone
Number of subjects: 223
Study 24710131 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone group
Number of subjects: 223
Study 24710131 — intervention group
Group type: COMPARATOR
Intervention: Control group (not treated with prednisolone)
Number of subjects: 223
Study 22565381 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-week rehabilitation group
Number of subjects: 82
Study 22565381 — intervention group
Group type: COMPARATOR
Intervention: 12-week rehabilitation group
Number of subjects: 82
Study 22565381 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 82
Study 20415915 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-surgical periodontal therapy
Number of subjects: 48
Study 20415915 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 48
Study 18607579 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat meal
Number of subjects: 0
Study 18607579 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat meal
Number of subjects: 0
Study 18607579 — intervention group
Group type: COMPARATOR
Intervention: Fasting condition
Number of subjects: 0
Study 16006422 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancer prevention intervention
Number of subjects: 0
Study 16006422 — intervention group
Group type: COMPARATOR
Intervention: Minimal-intervention control
Number of subjects: 0
Study 14664685 — intervention group
Group type: EXPERIMENTAL
Intervention: Nested provider effects treated as fixed
Number of subjects: 0
Study 14664685 — intervention group
Group type: COMPARATOR
Intervention: Nested provider effects treated as random
Number of subjects: 0
Study 10947134 — intervention group
Group type: EXPERIMENTAL
Intervention: Eschar debridement at 48 hours after cryosurgery
Number of subjects: 84
Study 10947134 — intervention group
Group type: COMPARATOR
Intervention: Standard care (no debridement)
Number of subjects: 84
Study 8852387 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea 500 mg twice daily
Number of subjects: 9
Study 8852387 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of hydroxyurea 500 mg twice daily and azidothymidine (AZT) 250 mg twice daily
Number of subjects: 9
Study 8852387 — intervention group
Group type: COMPARATOR
Intervention: Azidothymidine (AZT) 250 mg twice daily
Number of subjects: 9
Study 1352931 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium (0.1 mg/kg) + Alfentanil (15 micrograms/kg)
Number of subjects: 42
Study 1352931 — intervention group
Group type: COMPARATOR
Intervention: Pancuronium (0.1 mg/kg) + Alfentanil (15 micrograms/kg)
Number of subjects: 42
Study 6371226 — intervention group
Group type: EXPERIMENTAL
Intervention: subject-alone relaxation therapy
Number of subjects: 48
Study 6371226 — intervention group
Group type: EXPERIMENTAL
Intervention: couples-relaxation therapy
Number of subjects: 48
Study 6371226 — intervention group
Group type: COMPARATOR
Intervention: couples-cognitive therapy
Number of subjects: 48
Study 31849458 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise plus nutrition (soy peptide supplementation)
Number of subjects: 67
Study 31849458 — intervention group
Group type: COMPARATOR
Intervention: Exercise only
Number of subjects: 67
Study 29280685 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted Training in Illness Management
Number of subjects: 200
Study 29280685 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 200
Study 27592690 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent adductor canal block (ACB) with 15 ml of 0.5% ropivacaine every 6 hours
Number of subjects: 50
Study 27592690 — intervention group
Group type: COMPARATOR
Intervention: Continuous adductor canal block (ACB) with 0.5% ropivacaine infusing at 2.5 ml/h
Number of subjects: 50
Study 27592690 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent ACB
Number of subjects: 50
Study 27592690 — intervention group
Group type: COMPARATOR
Intervention: Continuous ACB
Number of subjects: 50
Study 25268806 — intervention group
Group type: EXPERIMENTAL
Intervention: β-glucan 1000 mg once daily for 7 days
Number of subjects: 15
Study 25268806 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 15
Study 22175661 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based expert system intervention
Number of subjects: 570
Study 22175661 — intervention group
Group type: EXPERIMENTAL
Intervention: Four-cluster solution
Number of subjects: 570
Study 22175661 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster analyses
Number of subjects: 570
Study 19858250 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (2 g doses given 24 h apart)
Number of subjects: 60
Study 19858250 — intervention group
Group type: COMPARATOR
Intervention: Sulfadoxine-pyrimethamine (1,500 mg or 75 mg) or chloroquine (450 mg base daily for 3 days)
Number of subjects: 60
Study 17991116 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal slingplasty (IVS) treatment
Number of subjects: 62
Study 16390772 — intervention group
Group type: EXPERIMENTAL
Intervention: 90 mg of daily genistein
Number of subjects: 100
Study 16390772 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 12170527 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH agonist therapy for endometriosis
Number of subjects: 0
Study 11237197 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA-rich oil capsules containing 1.5-1.8 g DHA/d
Number of subjects: 41
Study 11237197 — intervention group
Group type: COMPARATOR
Intervention: Control oil capsules containing 97% soybean oil plus 3% fish oil
Number of subjects: 41
Study 8874525 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocolloid dressing
Number of subjects: 0
Study 8874525 — intervention group
Group type: COMPARATOR
Intervention: Moisturizer
Number of subjects: 0
Study 1509912 — intervention group
Group type: EXPERIMENTAL
Intervention: Mannitol solution at 400 mOsm/kg (Group 1)
Number of subjects: 41
Study 1509912 — intervention group
Group type: EXPERIMENTAL
Intervention: Mannitol solution plus allopurinol (Group 2)
Number of subjects: 41
Study 1509912 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall incidence
Number of subjects: 41
Study 1509912 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-hour initial diuresis
Number of subjects: 41
Study 6233188 — intervention group
Group type: EXPERIMENTAL
Intervention: Motretinide 0.1% vanishing cream
Number of subjects: 30
Study 6233188 — intervention group
Group type: COMPARATOR
Intervention: Benzoyl peroxide 5% gel
Number of subjects: 30
Study 31351241 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-Child Interaction Therapy-informed behavioral treatment
Number of subjects: 31
Study 30021201 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT)
Number of subjects: 721
Study 30021201 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 721
Study 28939544 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based aftercare program (IN@)
Number of subjects: 253
Study 28939544 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 253
Study 25759972 — intervention group
Group type: EXPERIMENTAL
Intervention: Agatston scoring (scores of 1-100)
Number of subjects: 1575
Study 25759972 — intervention group
Group type: EXPERIMENTAL
Intervention: Agatston scoring (scores of 101-1000)
Number of subjects: 1575
Study 25759972 — intervention group
Group type: EXPERIMENTAL
Intervention: Agatston scoring (scores greater than 1000)
Number of subjects: 1575
Study 25759972 — intervention group
Group type: EXPERIMENTAL
Intervention: Summed segmented vessel-specific scores (scores of 1-5)
Number of subjects: 1575
Study 25759972 — intervention group
Group type: EXPERIMENTAL
Intervention: Summed segmented vessel-specific scores (scores of 6-11)
Number of subjects: 1575
Study 25759972 — intervention group
Group type: EXPERIMENTAL
Intervention: Summed segmented vessel-specific scores (scores of 12-30)
Number of subjects: 1575
Study 25759972 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall visual assessment (mild)
Number of subjects: 1575
Study 25759972 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall visual assessment (moderate)
Number of subjects: 1575
Study 25759972 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall visual assessment (heavy)
Number of subjects: 1575
Study 23845200 — intervention group
Group type: EXPERIMENTAL
Intervention: TrP therapy (manual pressure applied to taut bands and passive stretching)
Number of subjects: 20
Study 23845200 — intervention group
Group type: COMPARATOR
Intervention: Simulated TrP therapy (no additional pressure, longitudinal stroking but no additional stretching)
Number of subjects: 20
Study 23845200 — intervention group
Group type: EXPERIMENTAL
Intervention: TrP therapy
Number of subjects: 20
Study 23845200 — intervention group
Group type: COMPARATOR
Intervention: Simulated TrP therapy
Number of subjects: 20
Study 21933376 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent screening and treatment (IST) of malaria
Number of subjects: 0
Study 18953260 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin
Number of subjects: 391
Study 18953260 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 391
Study 16403592 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructose supplementation (7.5 g) tri‐daily after each main meal
Number of subjects: 26
Study 16403592 — intervention group
Group type: COMPARATOR
Intervention: Maltodextrin supplementation (7.5 g) tri‐daily after each main meal
Number of subjects: 26
Study 16403592 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructose supplementation
Number of subjects: 26
Study 16403592 — intervention group
Group type: COMPARATOR
Intervention: Maltodextrin supplementation
Number of subjects: 26
Study 14665349 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral resection of the prostate (TURP)
Number of subjects: 141
Study 14665349 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact laser prostatectomy
Number of subjects: 141
Study 14665349 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrovaporization
Number of subjects: 141
Study 14665349 — intervention group
Group type: COMPARATOR
Intervention: All treatment groups
Number of subjects: 141
Study 11188390 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training
Number of subjects: 0
Study 11188390 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training with biofeedback
Number of subjects: 0
Study 9377069 — intervention group
Group type: EXPERIMENTAL
Intervention: Large-volume leukapheresis
Number of subjects: 17
Study 8242506 — intervention group
Group type: EXPERIMENTAL
Intervention: MMR vaccine administered at 13 months
Number of subjects: 376
Study 8242506 — intervention group
Group type: EXPERIMENTAL
Intervention: MMR vaccine administered at 15 months
Number of subjects: 376
Study 8242506 — intervention group
Group type: COMPARATOR
Intervention: MMR vaccine (both groups)
Number of subjects: 376
Study 3011174 — intervention group
Group type: EXPERIMENTAL
Intervention: Weighted traction
Number of subjects: 0
Study 3011174 — intervention group
Group type: COMPARATOR
Intervention: Simulated traction
Number of subjects: 0
Study 30116551 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIG) therapy
Number of subjects: 0
Study 30116551 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 0
Study 27363988 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic dance programme (60 minutes, 3 times a week for 3 months)
Number of subjects: 36
Study 27363988 — intervention group
Group type: COMPARATOR
Intervention: Colouring and handwriting activities (control group)
Number of subjects: 36
Study 27363988 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic dance programme
Number of subjects: 36
Study 25049325 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling with results of psychosocial questionnaire provided to counselors before the session
Number of subjects: 246
Study 23363776 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (25,000 IU retinyl palmitate per day for 4 months)
Number of subjects: 0
Study 23363776 — intervention group
Group type: COMPARATOR
Intervention: Placebo (one capsule per day for 4 months)
Number of subjects: 0
Study 23363776 — intervention group
Group type: COMPARATOR
Intervention: Control (healthy controls)
Number of subjects: 0
Study 23363776 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation
Number of subjects: 0
Study 23363776 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 23363776 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study 20829329 — intervention group
Group type: EXPERIMENTAL
Intervention: T/FAC (weekly paclitaxel × 12 followed by FAC × 4)
Number of subjects: 273
Study 20829329 — intervention group
Group type: COMPARATOR
Intervention: FAC (FAC × 6)
Number of subjects: 273
Study 18027040 — intervention group
Group type: EXPERIMENTAL
Intervention: Graduated balloon dilation
Number of subjects: 42
Study 18027040 — intervention group
Group type: COMPARATOR
Intervention: Bougie-over-a-guidewire dilation
Number of subjects: 42
Study 18027040 — intervention group
Group type: COMPARATOR
Intervention: Handsewn anastomoses
Number of subjects: 42
Study 18027040 — intervention group
Group type: COMPARATOR
Intervention: Combined stapled and handsewn anastomoses
Number of subjects: 42
Study 15930095 — intervention group
Group type: EXPERIMENTAL
Intervention: Crit-Line monitoring
Number of subjects: 443
Study 15930095 — intervention group
Group type: COMPARATOR
Intervention: Conventional monitoring
Number of subjects: 443
Study 12502991 — intervention group
Group type: EXPERIMENTAL
Intervention: Preemptive epidural analgesia followed by PCEA (PA + PCEA)
Number of subjects: 0
Study 12502991 — intervention group
Group type: COMPARATOR
Intervention: PCEA
Number of subjects: 0
Study 11220522 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine 15 mg once daily
Number of subjects: 91
Study 11220522 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study 8695089 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure support (PS) titrated to produce a tidal volume (VT) of 8 ml/kg body weight
Number of subjects: 20
Study 8695089 — intervention group
Group type: COMPARATOR
Intervention: Pressure support (PS) at 5 cmH2O
Number of subjects: 20
Study 7949749 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclic oestrogen/progestogen therapy (group 1, n = 20)
Number of subjects: 74